Furthermore, we demonstrate that the defective cell cycle regulation pathway caused by p16INK4A inactivation can be therapeutically exploited using the selective CDK4/CDK6 inhibitor palbociclib in both 2D and 3D in vitro culture models of osteosarcoma cell lines. Here, CDKN2A is linked to osteosarcoma.